Angiotensin converting enzyme inhibition in plasma and tissues.
Angiotensin converting enzyme (ACE) and the ACE inhibitor lisinopril were measured in patients with renal impairment, by both radioinhibitor 125I MK351A binding studies, and by radioimmunoassay. Plasma concentration of lisinopril estimated by radioinhibitor binding displacement correlated closely with that measured by radioimmunoassay. Plateau lisinopril concentration in 8 patients with varying degrees of renal failure treated with 5 mg lisinopril per day for 1 week, was inversely related to renal function. Plasma lisinopril concentrations of 30-70 ng/ml were required for 50% inhibition of plasma ACE activity in vivo. Acute studies in the rat showed inhibition of ACE in different tissues had different time courses. These observations suggest that 125I MK351A binding studies in tissues will be useful in establishing the pharmacokinetic and pharmacodynamic profiles of newer ACE inhibitors, and may help delineate the contribution of ACE in different tissues to cardiovascular homeostasis.
D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D004151:Dipeptides / Q000378:metabolism; D004656:Enalapril / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000201:enzymology; D007677:Kidney Function Tests; D007700:Kinetics; D017706:Lisinopril; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D011485:Protein Binding; D051381:Rats
D000806:Angiotensin-Converting Enzyme Inhibitors; D004151:Dipeptides; C042037:L-proline, N2-((1S)-1-carboxy-3-phenylpropyl)-N6-((4-hydroxyphenyl)iminomethyl)-L-lysyl-; D004656:Enalapril; D017706:Lisinopril; D007703:Peptidyl-Dipeptidase A